Here's Shares Agios Pharmaceuticals: 2026 Outlook and Rally
Biotech investors watched Agios Pharmaceuticals spark a notable rally after key quarterly results and a strong Aqvesm...
Trying to decide which is better: cash back or points credit cards? Analyze your spending habits to make the best choice for maximizing rewards.
27,088 articlesBiotech investors watched Agios Pharmaceuticals spark a notable rally after key quarterly results and a strong Aqvesm...
Famed investor Michael Burry reportedly tacks a bearish stance onto Micron Technology, signaling renewed caution for ...
New documents reveal Epstein used elite ties to influence major philanthropy groups, raising questions about governan...
An ESG equity fund has posted a double-digit gain while steering clear of Meta. Its AI-forward lineup centers on Alph...
Bitcoin hovered near $80,000 as April payrolls undershot forecasts, renewing bets on Fed policy and a potential bitco...
As July 18, 2026 approaches, the GENIUS Act deadline accelerates rulemaking for stablecoin issuers. Regulators from T...
A new defense startup is challenging traditional missiles with a car-like manufacturing model, backed by a $5 million...
As AI models scale, memory bandwidth becomes the bottleneck. This article digs into Nvidia's role in HBM4, the chatte...
A veteran wealth manager bets international exposure through a broad non-U.S. ETF to diversify risk and tap growth ou...
A sudden regulatory shift around tokenized stocks has sparked a wave of excitement and confusion. This Morning Minute...
XOVR, the $1.5 billion ETF that blends pre-IPO SpaceX exposure with public-growth stocks, is drawing renewed scrutiny...
Oil futures closed above $100 a barrel for the first time in years, driven by Iran's vow to block the Strait of Hormu...